EQS-News: Xtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity
Werte in diesem Artikel
EQS-News: B2i Digital, Inc.
/ Key word(s): Financial
Werbung Werbung The Partnership Will Deliver Centralized, Investor-focused Content to Help Retail and Institutional Audiences Gain Insight Into Xtant’s Orthobiologics Platform and Long-term Value Proposition NEW YORK, NY - July 28, 2025 (NEWMEDIAWIRE) - B2i Digital is pleased to announce that Xtant Medical Holdings (NYSE American: XTNT) has been named a B2i Digital Featured Company. Xtant is a global medical technology company that develops, manufactures, and markets a full-service portfolio of regenerative medicine products and related medical devices for orthopedic and neurosurgical specialists. The company’s vertically integrated model allows it to offer a full-service product line that includes bone-healing grafts, growth-factor biologics, cellular allografts, synthetics, and amnion products. This integration, combined with a robust R&D pipeline that includes multiple next-generation biologics scheduled for launch through 2025, underpins its strategy for driving margin improvement and long-term, sustainable growth. Werbung Werbung “We are pleased to showcase Xtant Medical to our investor community at this pivotal time in the company’s expansion and evolution,” said David Shapiro, CEO of B2i Digital. “With its vertically integrated platform covering all five major orthobiologic categories and a clear trajectory of revenue growth, the company presents a compelling story for investors interested in the medical technology sector. Xtant’s established distribution network and robust product pipeline position it well within a multi-billion-dollar market.” Sean Browne, CEO of Xtant Medical, commented, “Our partnership with B2i Digital will help us share our growth story and the value of our comprehensive biologics platform to the investment community. We are focused on execution and believe this collaboration will enhance our connection with current and prospective shareholders.” Xtant Medical has demonstrated strong business fundamentals, reporting fiscal year 2024 revenue of $117.5 million, a 29% year-over-year increase. The company has established significant market access through 450 integrated delivery network (IDN) contracts and a network of over 670 independent distributors, serving a $2.5 billion U.S. orthobiologics market within a $10.1 billion global spine market. Werbung Werbung About B2i Digital, Inc. B2i Digital, Inc. partners with investor conferences, public companies, and capital markets advisors through its Featured Conference, Featured Company, and Featured Expert programs. The firm leverages digital marketing technologies, a network of 1.3 million investors, and targeted introductions to connect key players in the markets. B2i Digital was founded in 2021 by David Shapiro, previously the Chief Marketing Officer and an investment banker at Maxim Group, LLC. David was also one of the founders of Maxim's investor awareness platform, M-Vest.com. B2i Digital Contact Information: David Shapiro https://www.linkedin.com/in/davidshapironyc About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers. Investor Contact Information: Kevin Gardner View the original release on www.newmediawire.com News Source: B2i Digital, Inc.
29.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | B2i Digital, Inc. |
United States | |
ISIN: | US98420P3082 |
EQS News ID: | 2175730 |
End of News | EQS News Service |
|
2175730 29.07.2025 CET/CEST
Übrigens: Xtant Medical und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Xtant Medical
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Xtant Medical
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Xtant Medical Holdings Inc Registered Shs
Analysen zu Xtant Medical Holdings Inc Registered Shs
Datum | Rating | Analyst | |
---|---|---|---|
15.11.2018 | Xtant Medical Buy | Maxim Group |
Datum | Rating | Analyst | |
---|---|---|---|
15.11.2018 | Xtant Medical Buy | Maxim Group |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Xtant Medical Holdings Inc Registered Shs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen